Another breathless media release has announced enrollment of the first patient into a Phase II clinical trial of yet another new form of high-intensity, focused ultrasound (HIFU) in men with low-risk and favorable, intermediate-risk, localized prostate cancer.
According to information in the Boston Herald earlier today, researchers at Brigham & Women’s Hospital in Boston (one of the main teaching hospitals associated with Harvard University) are testing a new form of technology to treat localized prostate cancer.
In addition to the French data previously referred to on this site, data from another, much larger cohort of men treated with focal, high-intensity focused ultrasound (focal HIFU) are also to be presented at the upcoming annual meeting of the American Urological Association.
A major plenary presentation at the upcoming annual meeting of the American Urological Association (AUA) will provide data from a rather small French trial of high-intensity focused ultrasound (HIFU) in the focal management of localized prostate cancer.
For several years now, the Ahmed/Emberton-led research team in the United Kingdom (UK) has published the majority of the detailed outcomes data from treatment of men with localized prostate cancer using high-intensity focused ultrasound (HIFU). This group has now given us 5-year outcomes on a cohort of > 550 patients.
A new paper in “the Red Journal” prvides some information about the potential of proton beam radiation therapy (PBRT) as a salvage therapy in men who have failed either cryotherapy or first-line high-intensity focused ultrasound (HIFU) as first-line therapy for localized prostate cancer.
A new report provides data from a prospective, single-center, Phase II trial of high-intensity focused ultrasound (HIFU) in prostate cancer hemiablation as a form of focal therapy. The study was carried out in Belgium.
For those able to access the February 2016 issue of the AUA News, it carries an interesting article outlining the U.S. Food and Drug Administration’s perspective on exactly why the agency decided to approve two forms of high-intensity focused ultrasound (HIFU) technology for the transrectal ablation of prostate tissue.
As predicted, the U.S. Food and Drug Administration apparently approved the Ablatherm brand of equipment for high-intensity focused ultrasound (HIFU) on November 9 for “the ablation of prostate tissue.”
A new paper in European Urology has suggested that men with localized prostate cancer who are treated by focal forms of high-intensity focused ultrasound (HIFU) have “a return to baseline International Index of Erectile Function — erectile and total International Index of Erectile Function scores” by 6 months after treatment which was maintained at 1 […]
Your sitemaster is pleased to be able to report a forthright and interesting discussion yesterday with Dr. Stephen Scionti about the current and future potential of high-intensity focused ultrasound (HIFU) in the treatment of prostate cancer.
Dr. Stephen Scionti is almost certainly the most experienced practitioner of high-intensity focused ultrasound (HIFU) as a first-line treatment for prostate cancer practicing in the USA today — although he has had to actually treat the vast majority of his patients outside of the USA.
As predicted in yesterday’s post about the nature of the approval of SonaCare Medical’s Sonablate technology as a “generic” form of treatment for prostate tissue ablation, we are likely to see rapid approval of the Ablatherm brand of HIFU technology here in America very soon as well.
According to a media release issued by SonaCare Medical early this morning, the company has received approval from the U.S. Food and Drug Administration (FDA) to market its Sonablate® 450 technology in the U.S.A. for prostate tissue ablation.